Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt

Amneal Pharmaceuticals, Inc.

2025-Q2 EPS reported $0.11 revenue$1,419,928,000

Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).
Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.
Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.
FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.